Open AccessTHE ROLE OF NEW BIOMARKERS IN ACUTE KIDNEY INJURY DETECTING IN CRITICAL CONDITION PATIENTS
Author(s) -
В. Х. Шарипова,
N.F. Berdiev Berdiev,
O. K. Lutfullaev Lutfullaev,
A Mikhliev
Publication year - 2021
Language(s) - English
DOI - 10.54185/tbem/vol14_iss3/a10
Subject(s) - acute kidney injury , medicine , kidney , biomarker , subclinical infection , renal function , lipocalin , creatinine , intensive care medicine , kidney disease , urology , gastroenterology , biology , biochemistry
Acute kidney injury is a polyetiologic syndrome that is a sudden decrease in kidney function over several days or weeks, causing the accumulation of nitrogenous compounds in the blood, with or without a decrease in urine output. Acute kidney injury is common in hospitalized patients and is associated with increased morbidity, mortality, and financial costs. Currently, acute kidney injury is diagnosed after the onset of symptoms; Available diagnostic tests (presence of creatinine in the blood, microscopy of urine, urine volume) have shortcomings in identifying subclinical acute kidney injury. The lack of therapeutic strategies leads to the fact that the treatment of acute kidney injury is carried out with the help of supportive therapies. Early acute kidney injury detection is essential to minimize damage. Experimental and clinical studies have identified a new biomarker that contribute to the earlier diagnosis of acute kidney injury. With their help, it can be determined that patients are at risk of acute kidney damage. In this review, the authors describe some of the most promising new AKI biomarkers (neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule (KIM-1), interleukin-18 (IL18), tissue inhibitor of metalloproteinase-2 (TIMP-2), protein -7, which binds insulin-like growth factor (IGFBP7)).